Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for irritable bowel syndrome
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Herbal Medicines for the Management of IrritableBowelSyndrome: A Systematic Review. IrritableBowelSyndrome (IBS) is a chronic digestive disorder, which is characterized by abdominal pain, bloating, diarrhea and constipation periods. The etiology is unknown. Based on the different mechanisms in the etiology, treatment focuses on controlling symptoms. Due to the longtime of syndrome, inadequacy of current treatments, financial burden for patients and pharmacologic effects, several patients
Ramosetron Reduces Symptoms of IrritableBowelSyndrome With Diarrhea and Improves Quality of Life in Women Previous studies have indicated that serotonin-3-receptor antagonists might have a sex-specific effect in patients with irritablebowelsyndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron
Underlying molecular and cellular mechanisms in childhood irritablebowelsyndromeIrritablebowelsyndrome (IBS) affects a large number of children throughout the world. The symptom expression of IBS is heterogeneous, and several factors which may be interrelated within the IBS biopsychosocial model play a role. These factors include visceral hyperalgesia, intestinal permeability, gut microbiota, psychosocial distress, gut inflammation, bile acids, food intolerance, colonic bacterial
Genetics of irritablebowelsyndromeIrritablebowelsyndrome (IBS) is a common condition with a complex and largely unknown etiology. There is no cure, and treatment options are mainly directed to the amelioration of symptoms. IBS causes reduced quality of life and poses considerable repercussions on health and socioeconomic systems. There is a heritable component in IBS, and genetic research is a valuable tool for the identification of causative pathways, which will provide important insight
Eluxadoline for IrritableBowelSyndrome with Diarrhea. Background Effective and safe treatments are needed for patients who have irritablebowelsyndrome (IBS) with diarrhea. We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist), in patients with IBS with diarrhea. Methods We randomly assigned 2427 adults who had IBS with diarrhea to eluxadoline (at a dose
Diet Low in FODMAPs Reduces Symptoms of IrritableBowelSyndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial A diet with reduced content of fermentable short-chain carbohydrates (fermentable oligo-, di-, monosaccharides, and polyols [FODMAPs]) has been reported to be effective in the treatment of patients with irritablebowelsyndrome (IBS). However, there is no evidence of its superiority to traditional dietary advice for these patients. We compared the effects
Trimebutine Maleate and Pinaverium Bromide for IrritableBowelSyndrome: A Review of the Clinical Effectiveness, Safety and Guidelines Trimebutine Maleate and Pinaverium Bromide for IrritableBowelSyndrome: A Review of the Clinical Effectiveness, Safety and Guidelines | CADTH.ca Find the information you need Trimebutine Maleate and Pinaverium Bromide for IrritableBowelSyndrome: A Review of the Clinical Effectiveness, Safety and Guidelines Trimebutine Maleate and Pinaverium Bromide (...) for IrritableBowelSyndrome: A Review of the Clinical Effectiveness, Safety and Guidelines Published on: November 30, 2015 Project Number: RC0721-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of trimebutine maleate for the treatment of patients with irritablebowelsyndrome? What is the clinical effectiveness and safety of pinaverium bromide for the treatment of patients with irritablebowel
Epidemiology of irritablebowelsyndrome in the former communist countries from Eastern Europe: a systematic review. The irritablebowelsyndrome (IBS) is a functional gastrointestinal disorder frequently encountered in clinical practice in Eastern Europe. Epidemiological data are diverging on this condition. Our objective was to assess the prevalence of IBS in the former communist countries from Eastern Europe (EE).We performed a systematic review study using data from PubMed. Many languages (...) , some having only local spreading, are spoken in EE, so we decided to look only for papers indexed in PubMed, which have at least an English summary or title. We searched PubMed using the following keywords: irritablebowelsyndrome, functional digestive disorders, prevalence, EE. Only relevant studies were selected for analysis.From more than 4000 papers retrieved by this search, we identified a few papers appropriate to this survey. The spectrum of prevalence values is wide in IBS. Prevalence
Probiotic for irritablebowelsyndrome in pediatric patients: a randomized controlled clinical trial. Irritablebowelsyndrome (IBS) is a common gastrointestinal disorder in children. Recently, probiotics have been suggested as a treatment option for gastrointestinal disorders. The most effective species and the most appropriate doses are still unknown.The aim of this study was to assess the effects of Lactobacillus GG (LGG) for treating IBS in pediatric patients.In a controlled, double blind (...) one, two, three, and four weeks of treatment, as indicated by P-values of 0.01, 0.00, 0.00, and 0.00, respectively. Also, there was significant improvement in the functional scale after two weeks of treatment (P-value ≤ 0.00).Lactobacillus GG at a concentration of 1×10(10) cfu/ml for a period of four weeks can lessen the severity of the patients' pain and improve the functional scale in patients with irritablebowelsyndrome. Probiotics can have therapeutic effects for IBS patients.
Linaclotide (Constella) in the symptomatic management of irritablebowelsyndrome with constipation, The indication was granted...so what? 2015. DAR No 4: Linaclotide. Constella® in the symptomatic management of irritablebowelsyndrome with constipation - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 4: Linaclotide. Constella® in the symptomatic management of irritablebowelsyndrome with constipation DAR No 4: Linaclotide. Constella (...) ® in the symptomatic management of irritablebowelsyndrome with constipation Content tools Share it The indication was granted...so what? Although authorized for irritablebowelsyndrome with constipation it offers only symptomatic relief. In the best of cases, one in five patients can benefit from treatment. On the other hand, one in five patients can suffer from diarrhea as a secondary effect which can last for more than 28 days in half the cases. There are no available studies evaluating
Irritablebowelsyndrome: new and emerging treatments. Irritablebowelsyndrome is one of the most common gastrointestinal disorders in developed nations. It is characterized by abdominal pain, altered bowel habits, and bloating. Several non-pharmacological and pharmacological agents, which target the peripheral gastrointestinal system and central nervous system, are used to treat the syndrome. The individual and societal impact of investigating and managing the syndrome is substantial (...) , and despite newer treatments, many patients have unmet needs. Intense research at many international sites has improved the understanding of pathophysiology of the syndrome, but developing treatments that are effective, safe, and that have tolerable side effects remains a challenge. This review briefly summarizes the currently available treatments for irritablebowelsyndrome then focuses on newer non-pharmacological and pharmacological therapies and recent evidence for older treatments. Recent guidelines
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritablebowelsyndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritablebowelsyndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try
IrritableBowelSyndrome (IBS) World Gastroenterology Organisation Global Guidelines IrritableBowelSyndrome: a Global Perspective Update September 2015 Review team Eamonn M.M. Quigley USA (Chair) Michael Fried Switzerland Kok-Ann Gwee Singapore Igor Khalif Russia Pali Hungin United Kingdom Greger Lindberg Sweden Zaigham Abbas Pakistan Luis Bustos Fernandez Argentina Shobna J. Bhatia India Max Schmulson Mexico Carolina Olano Uruguay Anton Le Mair The Netherlands WGO Global Guidelines IBS 2 (...) Diagnostic criteria (Rome III) 12 4.2 Additional tests or investigatations 13 4.3 Differential diagnosis 13 4.4 Comorbidity with other diseases 17 5 Management of IBS 17 5.1 Introduction 17 5.2 Diet 19 5.3 Drug therapy 20 5.4 Psychological and other treatments 23 5.5 Prognosis 24 5.6 Follow-up 25 6 Appendix: useful resources 25 References 26 Figures Fig. 1 Algorithm for diagnosing irritablebowelsyndrome (IBS) 11 Fig. 2 Management of patients with symptoms of irritablebowelsyndrome 18 Tables Table 1
Viberzi (eluxadoline) - To treat irritablebowelsyndrome with diarrhea (IBS-D) in adult men and women Viberzi (eluxadoline) Tablets U.S. Department of Health and Human Services Search FDA Submit search Viberzi (eluxadoline) Tablets Viberzi (eluxadoline) Tablet Company: Furiex Pharmaceuticals, Inc. Application No.: 206940 Approval Date: 05/27/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF